Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KAINAIR vs AEROLATE SR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Kainair is a selective agonist for kainate receptors, which are ionotropic glutamate receptors. It depolarizes neurons by increasing sodium and calcium conductance, leading to excitatory neurotransmission and neurotoxicity at high doses.
AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.
Refractory partial-onset seizures (adjunctive therapy),Off-label: Research tool for excitotoxicity studies
Treatment of symptoms and reversible airway obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
25 mg subcutaneously three times daily.
400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.
3-5 hours, prolonging in renal impairment (up to 12-18 hours in GFR <30 m L/min).
Terminal elimination half-life 12 hours (range 10–15 h) in adults; prolonged in hepatic impairment (up to 24 h) and elderly.
Primarily metabolized by CYP3A4 and CYP2C9 isoenzymes. Undergoes hydrolysis to inactive metabolites.
Primarily hepatic via cytochrome P450 enzymes (CYP1A2, CYP2E1, and CYP3A4). Theophylline is metabolized to 1,3-dimethyluric acid, 1-methyluric acid, and 3-methylxanthine.
Primarily renal (approximately 90% unchanged drug within 24 hours), with minor biliary/fecal elimination (<10%).
Renal: 60% as unchanged drug; biliary/fecal: 30% as metabolites; 10% as unchanged in feces.
92-98% bound, primarily to α1-acid glycoprotein.
55–65% bound to plasma proteins, primarily albumin.
0.3-0.5 L/kg, indicating limited extravascular distribution.
0.4–0.6 L/kg, indicating distribution into total body water.
Intravenous 100%; intramuscular 65-75%; oral <5% due to extensive first-pass metabolism.
Oral: 90–100% for sustained-release formulation; food decreases rate but not extent (AUC unchanged).
e GFR 30-89 m L/min: No adjustment. e GFR <30 m L/min: Not recommended.
No dose adjustment required for renal impairment.
Child-Pugh A or B: No adjustment. Child-Pugh C: Contraindicated.
Use with caution in severe hepatic impairment (Child-Pugh class C); consider dose reduction by 50%.
Not approved for use in pediatric patients.
Children 6-12 years: 200-400 mcg inhaled twice daily. Children over 12 years: same as adult dose.
No specific dose adjustment; use with caution due to potential for altered clearance.
Start at lower end of dosing range (400 mcg twice daily) and titrate to response; monitor for systemic effects.
None.
No FDA black box warning exists for this drug.
Risk of neurotoxicity at high doses or rapid infusion,Can worsen seizure control in some epilepsy syndromes,Monitor liver function due to CYP metabolism,May cause dizziness, ataxia, and cognitive impairment
Theophylline has a narrow therapeutic index; serum levels must be monitored to avoid toxicity. Toxicity can include seizures, cardiac arrhythmias, and death. Caution in patients with heart failure, hepatic impairment, or those over 55 years. Risk of toxicity increased by concurrent medications such as cimetidine, fluoroquinolones, and macrolides.
Hypersensitivity to kainate receptor agonists,Severe hepatic impairment,Status epilepticus (non-approved indication)
Hypersensitivity to theophylline or any component of the formulation; active seizure disorder; untreated cardiac arrhythmias; severe hypertension; hyperthyroidism; peptic ulcer disease; caution with concurrent use of ephedrine or other sympathomimetics.
No specific food interactions, but alcohol consumption increases risk of gastrointestinal bleeding. Maintain adequate hydration to reduce renal toxicity.
High-fat meals may delay absorption. Avoid charcoal-grilled foods and large amounts of caffeine. Grapefruit juice may increase theophylline levels; limit intake.
Kainair (approval pending) is an adenosine receptor antagonist. Data insufficient. First trimester: theoretical risk based on animal studies showing dose-dependent embryotoxicity at supraclinical doses (reduced fetal weight, increased resorptions). Second/third trimester: no human data; may cause fetal tachycardia due to adenosine receptor blockade. Avoid use unless potential benefit outweighs risk.
Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypoglycemia, and reduced uterine contractility; avoid use near term due to potential for neonatal bradycardia and hypoglycemia.
No data on excretion in human milk. M/P ratio unknown. Due to small molecular weight, possible transfer to infant. Risk of infant CNS stimulation and tachycardia. Avoid breastfeeding during therapy and for at least 5 half-lives after last dose.
Salbutamol is excreted into breast milk in minimal amounts; estimated infant dose <2% of maternal weight-adjusted dose. No known adverse effects in nursing infants. M/P ratio not established. Use with caution.
No established dose adjustments for pregnancy. Increased plasma volume and renal clearance in pregnancy may reduce drug exposure, potentially requiring higher doses, but no evidence exists. Use lowest effective dose with careful monitoring of maternal and fetal response. Avoid in third trimester due to risk of fetal tachycardia.
No dose adjustment required for inhaled salbutamol. Increased clearance in late pregnancy may necessitate higher doses for systemic effects; monitor clinical response and adjust accordingly.
KAINAIR (ketorolac tromethamine) is an NSAID for short-term management of moderate to severe acute pain, not to exceed 5 days. Monitor renal function, especially in elderly, dehydrated, or on diuretics. Contraindicated in peptic ulcer disease, bleeding disorders, and renal impairment. Use lowest effective dose; co-administration with other NSAIDs or aspirin increases bleeding risk. Intramuscular injection: give deeply; do not use epidural or intrathecal route due to neurotoxicity.
AEROLATE SR contains theophylline; narrow therapeutic index (10-20 mcg/m L). Monitor serum levels, especially with CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) or inducers (e.g., carbamazepine, phenytoin). SR formulation avoids peak-trough fluctuations; do not crush or chew. Caution in heart failure, hepatic impairment, and elderly.
Take this medication exactly as prescribed for the shortest duration necessary, usually no more than 5 days.,Avoid taking other NSAIDs (e.g., ibuprofen, naproxen) or aspirin while using this drug.,Report any signs of gastrointestinal bleeding (black stools, vomiting blood), easy bruising, or kidney problems (changes in urination, swelling) immediately.,This drug may cause dizziness or drowsiness; avoid driving or operating machinery until you know how it affects you.,Do not drink alcohol while taking this medication, as it increases the risk of stomach bleeding.,If you are pregnant, especially in the third trimester, do not use; avoid if breastfeeding.
Take exactly as prescribed; do not crush or chew the sustained-release tablet.,Do not stop suddenly; sudden withdrawal may worsen breathing.,Avoid excessive caffeine (coffee, tea, chocolate) as it may increase side effects.,Report nausea, vomiting, insomnia, palpitations, or seizures immediately.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KAINAIR vs AEROLATE SR, answered by our medical review team.
KAINAIR is a Bronchodilator that works by Kainair is a selective agonist for kainate receptors, which are ionotropic glutamate receptors. It depolarizes neurons by increasing sodium and calcium conductance, leading to excitatory neurotransmission and neurotoxicity at high doses.. AEROLATE SR is a Bronchodilator that works by AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KAINAIR and AEROLATE SR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KAINAIR is: 25 mg subcutaneously three times daily.. The standard adult dose of AEROLATE SR is: 400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KAINAIR and AEROLATE SR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KAINAIR is classified as Category C. Kainair (approval pending) is an adenosine receptor antagonist. Data insufficient. First trimester: theoretical risk based on animal studies showing dose-dependent embryotoxicity a. AEROLATE SR is classified as Category C. Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.